The COVID crisis throws into relief what happens when grief has—quite literally—nowhere to go. The evidence suggests that most people summon strengths that surpass their own expectations.
Verified by Psychology Today
A resource for patients and families
Charles Zorumski M.D., Eugene Rubin M.D., Ph.D.
COVID-19 can cause brain-related complications, including new-onset psychosis and strokes.
In two longitudinal studies, there was a strong association between attendance at religious services and fewer deaths related to suicide, drugs, and alcohol.
Will the COVID-19 pandemic cause physicians, medical centers, and hospitals to return to core values?
Treatment with an intensive form of TMS may lead to improvement for patients with severe, treatment-resistant depression.
COVID-19 influences brain function and can cause neurologic and psychiatric symptoms. Psychiatrists are involved in studies defining disease mechanisms and developing treatments.
Treating ADHD with stimulant medications may help reduce suicidal behavior. This effect is not observed with non-stimulant medication for ADHD.
The majority of individuals suffering from mood, anxiety, and substance use disorders do not receive any type of treatment.
Increasing evidence suggests that microbes living in our gastrointestinal system can influence brain function and behavior.
Studies indicate that a brief course of medication or brain stimulation coupled with psychological treatment may lead to relief for two complex disorders.
Young children at risk for schizophrenia have significant differences in cognitive functioning when compared to children at risk for bipolar disorder and controls.
Two recently approved antidepressant medications may represent the beginning of a second revolution in psychopharmacology.
An important study indicates that alcohol and drug use are major contributors to the overall burden of disease worldwide.
A recent study provides evidence that anorexia nervosa is both a psychiatric and metabolic disorder.
Early diagnosis of bipolar disorder is important so that appropriate treatments can be initiated. However, diagnosis can be challenging. Why?
Suicide rates in the U.S. have increased about 35 percent since the year 2000. Death rates from unintentional overdoses, however, have increased 450 percent over the same period.
When adults report being maltreated as children, are their reports always accurate? When children experience maltreatment, do they recall it later as adults?
A study of health claims data demonstrates that the use of medications to treat ADHD is associated with a decrease in later substance use-related events.
Substantial progress is being made to develop blood tests that can detect early stages of brain degeneration.
Should physician-assisted death be allowed for psychiatrically ill patients who find the suffering from their disorders unbearable?
A 2018 study indicates that differences in cognitive function can be detected at a very early age in individuals who are later diagnosed with schizophrenia.
A recently approved drug to treat seizures may also have clinically significant antidepressant properties.
Recent genetic data support the possibility of a common factor underlying multiple psychiatric disorders.
Persons with ALS often demonstrate behavioral changes. Research indicates that their family members may have an increased risk of certain psychiatric disorders.
Primary care providers will become more involved in screening for a variety of psychiatric conditions.
Traumatic brain injuries are associated with increased rates of suicide even in those without pre-existing psychiatric conditions.
A specific parent-child therapy substantially decreases depressive symptoms in very young children and offers hope of diminishing longer-term consequences.
In a study, two 8-hour MDMA-assisted psychotherapy sessions, together with extensive follow-up, led to substantial improvement in PTSD symptoms.
Several mechanistically different treatments have been proposed for PTSD. A type of mindfulness-based treatment can now be added to this list.
Research indicates that 10 percent of adults experienced depression during the previous year. About 50 percent of those had received some sort of treatment.
Psychedelics may have therapeutic value for people with certain psychiatric disorders. But are the individual and societal risks worth it?
Charles F. Zorumski, MD, is Samuel B. Guze Professor and Head of Psychiatry at Washington University in St. Louis - School of Medicine.
Eugene Rubin, M.D., Ph.D., is Professor and Vice-Chair for Education in the Department of Psychiatry at Washington University in St. Louis - School of Medicine.